Register Login
Register to leave comments
  • News bot Oct. 1, 2025, 3:48 p.m.

    📋 Nkarta, Inc. (NKTX) - Financial Results

    Filing Date: 2022-05-12

    Accepted: 2022-05-12 16:09:28

    Event Type: Financial Results

    Event Details:

    Nkarta Inc (NKTX) Reports Q2 2022 Financial Results Nkarta Inc (NKTX) announced its financial results for the period ending Q2 2022. Key Financial Highlights:
    • Revenue: Not disclosed
    • Net Income: Not disclosed
    • EPS: Not disclosed
    • Cash and equivalents: 219055
      • targeting NKG2D ligands on tumor cells. NKG2D, a key activating receptor found on naturally occurring NK cells, induces a cell-killing immune response through the detection of stress ligands that are widely expressed on cancer cells. NKX101 is also engineered with membrane-bound form of interleukin-15 (IL15) for greater persistence and activity without exogenous cytokine support. To learn more about the NKX101 clinical trial in adults with AML or MDS, please visit ClinicalTrials.gov. About NKX019NKX019 is an allogeneic, cryopreserved, off-the-shelf cancer immunotherapy candidate that uses natural killer (NK) cells derived from the peripheral blood of healthy adult donors. It is engineered with a humanized CD19-directed CAR for enhanced tumor cell targeting and a proprietary, membrane-bound form of interleukin-15 (IL-15) for greater persistence and activity without exogenous cytokine support. CD19 is a biomarker for normal and malignant B cells, and it is a validated target for B cell cancer therapies. To learn more about the NKX019 clinical trial in adults with advanced B cell malignancies, please visit ClinicalTrials.gov. About NkartaNkarta is a clinical-stage biotechnology company advancing the development of allogeneic, off-the-shelf natural killer (NK) cell therapies for cancer patients. By combining its cell expansion and cryopreservation platform with proprietary cell engineering technologies and CRISPR-based genome engineering capabilities, Nkarta is building a pipeline of future cell therapies engineered for deep anti-tumor activity and intended for broad access in the outpatient treatment setting. For more information, please visit the company’s website at www.nkartatx.com. Cautionary Note on Forward-Looking Statements Statements contained in this press release regarding matters that are not historical facts are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995

    📊 Key Financial Metrics (Year-over-Year Comparison):

    Metric 2022 2021 Change ($) Change (%)
    Operating Expenses Loss From Operations 26.10K 19.48K $6.62K +33.97%
    Other Income Expense Net Interest Income 112.00 110.00 $2.00 +1.82%
    Other Income Expense Net Total Other Income Expense 111.00 108.00 $3.00 +2.78%
    Other Income Expense Net Net Loss 25.99K 19.37K $6.61K +34.14%
    Other Income Expense Net Net Loss Per Share 0.79 0.59 $0.20 +33.90%
    Other Income Expense Net Weighted Average Shares 32.99M 32.74M $252.97K +0.77%
    Assets Property Equipment Net 14.05K 12.86K $1.20K +9.31%
    Assets Operating Lease Right Of Use Assets 65.47K 11.68K $53.79K +460.62%
    Assets Other Assets 7.72K 9.18K $-1.46K -15.91%
    Liabilities And Stockholders Equity Operating Lease Liabilities 69.25K 12.46K $56.79K +455.78%
    Loss from Operations 26.10K 19.48K $6.62K +33.97%
    Interest Income 112.00 110.00 $2.00 +1.82%
    Total Other Income/(Expense) 111.00 108.00 $3.00 +2.78%
    Net Loss 25.99K 19.37K $6.61K +34.14%
    Property and Equipment, Net 14.05K 12.86K $1.20K +9.31%
    Other Assets 7.72K 9.18K $-1.46K -15.91%
    Accounts Payable 8.35K 10.48K $-2.13K -20.32%
    Operating Lease Liabilities 69.25K 12.46K $56.79K +455.78%

    💼 Business Developments:

    • Partnership: Not available
    • Acquisition: Not available
    • Licensing: Not available
    • Regulatory Approval
    • Executive Changes: Not available

    Structured Data:

    • Company Name: Nkarta Inc
    • CIK: 0001787400
    • Ticker Symbol: NKTX
    • Period End Date: 2022-05-12
    • Document Type: 8-K

Search

News categories